

CLAIMS

1. A prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors.

5

2. A prophylactic antimigraine agent as claimed in Claim 1, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises a) a 5-HT_{2B} receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT_{2B} receptor, and b) a 5-HT₇ receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT₇ receptor.

10

3. A prophylactic antimigraine agent as claimed in Claim 1, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises a dual antagonistic compound for the 5-HT_{2B} and 5-HT₇ receptors having a selective binding affinity to both of the 5-HT_{2B} and 5-HT₇ receptors.

15

4. A combined prophylactic preparation for migraine which comprises a) a first pharmaceutical preparation comprising as an active ingredient a 5-HT_{2B} receptor antagonistic compound having a selective binding affinity to the 5-HT_{2B} receptor, and b) a second pharmaceutical preparation comprising as an active ingredient a 5-HT₇ receptor antagonistic compound having a selective binding affinity to the 5-HT₇ receptor, and wherein the first and second preparations are administered simultaneously or separately.

20

5. A prophylactic antimigraine agent as claimed in Claim 1, wherein the binding affinity for the 5-HT_{2B} and 5-HT₇ receptors is respectively one-hundredth or less to the α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

25

6. Use of the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors for the manufacture of a prophylactic antimigraine agent.

5 7. Use of "a 5-HT_{2B} receptor antagonistic compound having a selective binding affinity to the 5-HT_{2B} receptor" for the manufacture of a prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors.

10 8. Use of "a 5-HT₇ receptor antagonistic compound having a selective binding affinity to the 5-HT₇ receptor" for the manufacture of a prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors.

15 9. A method for prophylaxis of migraine which comprises administering a therapeutically effective amount of a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors to a patient.

20 10. A method for prophylaxis of migraine which comprises administering a combination comprising a pharmaceutical preparation containing as an active ingredient a 5-HT_{2B} selective receptor antagonistic compound and a pharmaceutical preparation containing as an active ingredient a 5-HT₇ receptor selective antagonistic compound, simultaneously or separately to a patient.